Literature DB >> 34369454

CMV and HSV Pneumonia After Immunosuppressive Agents for Treatment of Cytokine Release Syndrome Due to Chimeric Antigen Receptor-modified T (CAR-T)-Cell Immunotherapy.

Madeleine R Heldman1,2, Jimmy Ma1, Jordan Gauthier3,4, Riley A O'Hara5, Andrew J Cowan3,4, Leah M Yoke1,2, Lisa So2, Elizabeth Gulleen1,2, Elizabeth R Duke1,2, Catherine Liu1,2,4, Cameron J Turtle3,4, Joshua A Hill1,2,4.   

Abstract

Pneumonia due to cytomegalovirus and herpes simplex virus-1 caused substantial morbidity after hematopoietic cell transplantation before the institution of preventative approaches. End-organ disease from herpesviruses is poorly described after chimeric antigen receptor-modified T-cell immunotherapy. We report 2 cases of cytomegalovirus pneumonia and 1 case of herpes simplex virus-1 gingivostomatitis, esophagitis, and pneumonia after chimeric antigen receptor-modified T-cell immunotherapy for the treatment of hematologic malignancies.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34369454      PMCID： PMC8497421          DOI： 10.1097/CJI.0000000000000388

Source DB:  PubMed          Journal:  J Immunother        ISSN： 1524-9557            Impact factor:   4.912


  10 in total

1.  Rapid detection of cytomegalovirus pulmonary infection by bronchoalveolar lavage and centrifugation culture.

Authors:  S W Crawford; R A Bowden; R C Hackman; C A Gleaves; J D Meyers; J G Clark
Journal:  Ann Intern Med       Date:  1988-02       Impact factor: 25.391

2.  Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation.

Authors:  Jose Paulo Martins; Christopher E Andoniou; Peter Fleming; Mariapia A Degli-Esposti; Geoffrey R Hill; Rachel D Kuns; Iona S Schuster; Valentina Voigt; Sheridan Daly; Antiopi Varelias; Siok-Keen Tey
Journal:  Science       Date:  2019-01-18       Impact factor: 47.728

3.  Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness: A Randomized Clinical Trial.

Authors:  Ajit P Limaye; Renee D Stapleton; Lili Peng; Scott R Gunn; Louise E Kimball; Robert Hyzy; Matthew C Exline; D Clark Files; Peter E Morris; Stephen K Frankel; Mark E Mikkelsen; Duncan Hite; Kyle B Enfield; Jay Steingrub; James O'Brien; Polly E Parsons; Joseph Cuschieri; Richard G Wunderink; David L Hotchkin; Ying Q Chen; Gordon D Rubenfeld; Michael Boeckh
Journal:  JAMA       Date:  2017-08-22       Impact factor: 56.272

4.  Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.

Authors:  Joshua A Hill; Daniel Li; Kevin A Hay; Margaret L Green; Sindhu Cherian; Xueyan Chen; Stanley R Riddell; David G Maloney; Michael Boeckh; Cameron J Turtle
Journal:  Blood       Date:  2017-10-16       Impact factor: 22.113

Review 5.  How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.

Authors:  Joshua A Hill; Susan K Seo
Journal:  Blood       Date:  2020-08-20       Impact factor: 22.113

6.  Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials.

Authors:  Per Ljungman; Michael Boeckh; Hans H Hirsch; Filip Josephson; Jens Lundgren; Garrett Nichols; Andreas Pikis; Raymund R Razonable; Veronica Miller; Paul D Griffiths
Journal:  Clin Infect Dis       Date:  2016-09-28       Impact factor: 9.079

7.  Cytomegalovirus (CMV) DNA Quantitation in Bronchoalveolar Lavage Fluid From Hematopoietic Stem Cell Transplant Recipients With CMV Pneumonia.

Authors:  Michael Boeckh; Terry Stevens-Ayers; Giovanna Travi; Meei-Li Huang; Guang-Shing Cheng; Hu Xie; Wendy Leisenring; Veronique Erard; Sachiko Seo; Louise Kimball; Lawrence Corey; Steven A Pergam; Keith R Jerome
Journal:  J Infect Dis       Date:  2017-05-15       Impact factor: 7.759

8.  Cytomegalovirus-induced immunopathology and its clinical consequences.

Authors:  Stefania Varani; Maria Paola Landini
Journal:  Herpesviridae       Date:  2011-04-07

9.  Reactivation of multiple viruses in patients with sepsis.

Authors:  Andrew H Walton; Jared T Muenzer; David Rasche; Jonathan S Boomer; Bryan Sato; Bernard H Brownstein; Alexandre Pachot; Terrence L Brooks; Elena Deych; William D Shannon; Jonathan M Green; Gregory A Storch; Richard S Hotchkiss
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

10.  Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.

Authors:  Jae H Park; F Andres Romero; Ying Taur; Michel Sadelain; Renier J Brentjens; Tobias M Hohl; Susan K Seo
Journal:  Clin Infect Dis       Date:  2018-08-01       Impact factor: 9.079
  10 in total
  1 in total

Review 1.  Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy.

Authors:  Kitsada Wudhikarn; Miguel-Angel Perales
Journal:  Bone Marrow Transplant       Date:  2022-07-15       Impact factor: 5.174
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.